MedWatch

Demant's top-line growth in line with outlook, Jefferies assesses

The investment bank has taken a look at a presentation from the Danish hearing aid company during the EUHA conference, and new numbers seem to match earlier announcements.

Photo: Richard Drew/AP/Ritzau Scanpix

Demant’s top-line growth looks to be in line with previous predictions, writes investment bank Jefferies after the Danish hearing aid manufacturer’s CEO, Søren Nielsen, and president for diagnostics and communications, Arne Boye Nielsen, took to the stage at industry conference EUHA.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs